Masupirdine (SUVN-502): An Update on the Phase-3 Clinical Development Program Targeting Agitation in Patients with Dementia of Alzheimer’s Type (P1-3.020)
To evaluate the efficacy, and safety of Masupirdine targeting agitation in patients with dementia of Alzheimer’s type
Authors
- Jyothsna Ravula
- Vijay Benade
- Vinod Goyal (ORCID: https://orcid.org/0000-0002-7325-1914)
- Ramakrishna Nirogi (ORCID: https://orcid.org/0000-0002-2045-0784)
- Venkat Jasti
- Veera Raghava Chowdary Palacharla (ORCID: https://orcid.org/0000-0001-7493-4920)
- Abdul Rasheed Mohammed (ORCID: https://orcid.org/0000-0001-7873-4600)
- Santosh Kumar Pandey
- Anil Shinde
- Pradeep Jayarajan
- Satish Jetta
- Ramkumar Subramanian
- Renny Abraham
Institutions
- Suven Life Sciences (India) (IN)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000209065
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00